Advanced Micro Devices, Inc. - Common Stock (AMD)
516.79
+8.86 (1.74%)
NASDAQ · Last Trade: Oct 23rd, 8:50 PM EDT
News & Press Releases
Taiwan Semiconductor (TSMC) Posted Record Profit and the Stock Still Fell. Here's What the Market Is Worried About.fool.com
The chipmaking giant is still firing on all cylinders, but investors are becoming more cautious.
Via The Motley Fool · October 23, 2026
AMD or Broadcom: If I Could Only Own 1 AI Chip Stock Through 2030, Here's My Pickfool.com
Both have strong medium-term outlooks, but one appears more reasonably valued right now.
Via The Motley Fool · October 23, 2026
If I Could Only Buy 1 AI Stock in November After This Sell-Off, It Would Be This One.fool.com
Astera Labs' sell-off last week may be a buying opportunity as its debt-free balance sheet, new PCIe 7 and Orion launches, and Nov. 3 earnings put its AI connectivity growth story in focus.
Via The Motley Fool · October 23, 2026
Why AMD Stock Fell on Thursdayfool.com
AMD fell as rising oil prices and Meta’s cash burn left investors questioning how long the AI spending boom can last.
Via The Motley Fool · October 22, 2026
What Does an AI Agent Need a CPU For? Why Nvidia Wants In on the Business Dominated by AMD and Intelfool.com
The GPU giant expects almost $20 billion in CPU sales this year.
Via The Motley Fool · October 22, 2026
AMD, Monolithic Power Systems, MACOM, Vishay Intertechnology, and Semtech shares plummet, what you need to know
What happened? A number of stocks fell in the afternoon session after warnings emerged that ongoing component supply chain bottlenecks and cleanroom space co...
Via StockStory · October 22, 2026
Where Will AMD Be in 2028?fool.com
AMD has a lot of growth priced into its stock already.
Via The Motley Fool · October 22, 2026
Not Intel. Not AMD. This Is the CPU Stock I'd Buy for the AI Agent Era.fool.com
Arm Holdings could be the biggest winner of the AI-fueled server CPU boom.
Via The Motley Fool · October 22, 2026
Investing in Artificial Intelligence (AI) Stocks Can be Risky, but This Might be a Great Way to Do Itfool.com
This exchange-traded fund invests in some of the world's best artificial intelligence stocks.
Via The Motley Fool · October 22, 2026
4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapymarketbeat.com
4D Molecular Therapeutics (NASDAQ:FDMT) used its first Investor Day to outline its development and commercial plans for 4D-150, an investigational intravitreal gene therapy for wet age-related macular degeneration, or wet AMD. Company executives and retina specialists described the therapy as a pote
Via MarketBeat · October 22, 2026
3 AI Stocks That Could Split in 2027fool.com
These stocks all trade at share prices that could make a split attractive.
Via The Motley Fool · October 22, 2026
REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapymarketbeat.com
REGENXBIO (NASDAQ:RGNX) outlined its clinical, manufacturing and commercialization plans for sura-vec, an investigational one-time subretinal gene therapy for wet age-related macular degeneration, or wet AMD, during a company event featuring retina specialists and executives.
The company said it ex
Via MarketBeat · October 21, 2026
$4,000 in These 4 Non-Nvidia Chip Stocks Could Be Worth This Much by 2030fool.com
Investing today in Broadcom, Marvell, AMD, and Arm could produce big returns by 2030.
Via The Motley Fool · October 21, 2026
MACOM, Semtech, FormFactor, Penguin Solutions, and Seagate stocks trade up, what you need to know
What happened? A number of stocks jumped in the afternoon session after strong demand for artificial intelligence hardware and robust corporate earnings reig...
Via StockStory · October 21, 2026
Western Digital, Nova, Amtech, Monolithic Power Systems, and Texas Instruments shares skyrocket, what you need to know
What happened? A number of stocks jumped in the afternoon session after strong demand for artificial intelligence hardware and robust corporate earnings reig...
Via StockStory · October 21, 2026
Teradyne, Vishay Intertechnology, Allegro MicroSystems, Entegris, and AMD shares are soaring, what you need to know
What happened? A number of stocks jumped in the afternoon session after strong demand for artificial intelligence hardware and robust corporate earnings reig...
Via StockStory · October 21, 2026
AMD vs. Nvidia. 1 Metric Proves Which Is the Best Stock.fool.com
AMD and Nvidia are two major competitors in the AI computing realm.
Via The Motley Fool · October 21, 2026
AMD Is Betting $8.2 Billion on the Next Phase of AIfool.com
AMD's latest AI move reaches far beyond today's chips. Here's what the deal could mean for future growth, competitive advantage, dilution, and the risks investors cannot ignore.
Via The Motley Fool · October 21, 2026
AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.
News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.
By Wall Street Investor · Via GlobeNewswire · October 21, 2026
The AI Buildout Is Only 15% Complete—Here Is Where the Next Dollar Actually Goesmarketbeat.com
AI spending is less than 15% complete in Dan Ives' view, with NVIDIA, Palantir, Meta and the neoclouds anchoring a bull run he sees lasting 2 to 3 more years.
Via MarketBeat · October 21, 2026
Advanced Micro Devices (AMD) Stock Plummeted 13% Last Week. Should You Buy the Dip Before Nov. 3?fool.com
AMD stock still looks expensive heading into its critical third-quarter earnings report.
Via The Motley Fool · October 21, 2026
Cathie Wood's Ark Invest Grew Its Portfolio to $15.4 Billion Last Quarter, With Tesla, AMD, and a New SpaceX Stake Making Up About 18% of ARKK Assets. Is Her Concentrated Bet Paying Off?fool.com
Cathie Wood has provocative ideas and has delivered some strong returns, but her firm's flagship ETF could be a risky bet for the future.
Via The Motley Fool · October 21, 2026
OpenAI Is Reportedly Raising $30 Billion. Which Chip Stock Gains the Most?fool.com
Which chipmaker has the most riding on the ChatGPT maker's ability to pay?
Via The Motley Fool · October 20, 2026
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Winmarketbeat.com
Ocular Therapeutix (NASDAQ:OCUL) is preparing a fourth-quarter new drug application submission for AXPAXLI, its investigational maintenance treatment for wet age-related macular degeneration, following discussions with the U.S. Food and Drug Administration, President and Chief Executive Officer Prav
Via MarketBeat · October 20, 2026
Chip Stocks Are Sliding—Why Is Smart Money Buying?marketbeat.com
SOXL fell about 20% in a month, but short interest dropped 65.6% and institutions like JPMorgan expanded holdings, signaling bets on a semiconductor sector rebound.
Via MarketBeat · October 20, 2026